Article Type

1 - 8 of 8 Results       Clear All

Azalea Therapeutics Launches With $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Gladstone in the News November 4, 2025

Azalea Therapeutics Launches With $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Azalea Therapeutics—Gladstone Investigators Jennifer Doudna and Justin Eyquem founded a new company to advance next-generation genomic medicines.

Business Development Gladstone Experts Doudna Lab Eyquem Lab

New Bay Area Spin-Off Company to Develop Drugs for Multiple Sclerosis and Alzheimer’s Disease

Founders of MedaRed
Article October 8, 2019

New Bay Area Spin-Off Company to Develop Drugs for Multiple Sclerosis and Alzheimer’s Disease

Senior Investigator Katerina Akassoglou has fundamentally changed the way scientists think of neurological disorders. She made the seminal discovery that blood leaks are toxic to the brain by promoting inflammation and destroying neurons. Her research led the scientific community to reassess the complex relationship between the brain, immune, and vascular systems.

Business Development Institutional News Assay Development and Drug Discovery Core Alzheimer’s Disease Multiple Sclerosis Neurological Disease Akassoglou Lab

Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s Disease

Article December 21, 2011

Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s Disease

SAN FRANCISCO and PRINCETON, NJ—December 22, 2011—Bristol-Myers Squibb Company (NYSE:BMY) and the Gladstone Institutestoday announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.

Business Development

More News

Are You a Journalist Looking to Write about Gladstone?

Explore Info for Media